Abstract 257P
Background
GTN comprises a unique group of tumours that originate from trophoblastic tissues which includes Invasive mole, choriocarcinoma and Placental site trophoblastic tumour and with proper treatment low-risk GTN is 100% curable. This study was carried out to evaluate the management outcome of low risk GTN patients to the accepted 1st line treatment regimens followed in the hospital.
Methods
205 patients of gestational trophoblastic disease who were registered at the institute between January 2016 and December 2018 were analysed retrospectively. Risk stratification & Staging was done according to Revised FIGO 2002 staging system. All low risk patients were included the study.
Results
Out of 205 ,46 (22%) patients were diagnosed with GTN (low-risk 43/205(21.5%). 37(86.04%) patients received single agent Methotrexate (weekly) while 4 (9.3%) patients received Actinomycin D (bi-weekly) as first line. Methotrexate/LV was given for 2 patients. 67.5%(n = 25/37) achieved Complete Response (CR) on Methotrexate while 32.4%(n = 12/37) went on to get second line.62.5%(n = 10/16) received ACT-D in second line while multi-drug chemotherapy was given to 5 patients (31%,5/16). CR was achieved in 84.62%(n = 11) in 2nd line while 1 patient went on to get 3rd line chemotherapy. Anemia was the most common complication associated with the disease and treatment.
Conclusions
Low- risk GTN is a highly chemo-sensitive tumor and 100% curable. methotrexate as single agent produced 67.5% of complete remission. Single agent methotrexate is still one of the preferred first-line regimes for low risk GTN.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
The author has declared no conflicts of interest.
Resources from the same session
41P - Clinical verification on the relationship between serum lipid metabolism and the immune microenvironment in breast cancer patients
Presenter: Wataru Goto
Session: Poster display session
Resources:
Abstract
42P - Genome wide copy number analysis of circulating tumour cells in breast cancer liver metastasis
Presenter: Saber Imani
Session: Poster display session
Resources:
Abstract
43P - A hotspot variants p.H1047R and p.H1047L in p110α/ΔNp63α complex affects structure, function and contributes to susceptibility metastatic breast cancer
Presenter: Zou Linglin
Session: Poster display session
Resources:
Abstract
44P - Correlation of circulating tumour cells with PET-CT in metastatic breast cancer
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract
45P - The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumour location
Presenter: Hubert Beaumont
Session: Poster display session
Resources:
Abstract
46P - Plasma soluble CD36 of breast cancer based on pathological and clinical characteristics
Presenter: Aditia Romadhoni
Session: Poster display session
Resources:
Abstract
47P - Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer
Presenter: MAYUKO MIKI
Session: Poster display session
Resources:
Abstract
48P - Development of MDA-MB-231-3D-Spheroid as a reliable model for studying Nav1.5 and nNav1.5-mediated breast cancer metastasis
Presenter: Ahmad Murtadha
Session: Poster display session
Resources:
Abstract
49P - Biochemical study on modifying role of variants of leptin gene and its receptor on serum leptin levels in breast cancer
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
50P - Prognostic factors of recurrence or distant metastasis in elderly breast cancer patients
Presenter: Seungju Lee
Session: Poster display session
Resources:
Abstract